Johnson & Johnson Single Dose Vaccine Behind in Production

In August of last year, Johnson & Johnson (J&J) signed a contract with the federal government promising to deliver an effective, one dose vaccine to Americans in 2021. Their goal was to produce 12 million doses by the end of next month, a number that they hoped would swell to 100 million by the end of June. Unfortunately, the company is currently two months behind in their production of the vaccine and it is unclear if they will be able to make up for the lost time. Despite the lag in their delivery of the vaccine, the company still plans to release the results from its trial in the coming weeks. Should J&J’s vaccine prove as effective as those already on the market, it will undoubtedly become the vaccine of choice for administrators and patients alike. In stark contrast to the Pfizer and Moderna vaccines, J&J’s is a single dose vaccine that can be stored for weeks in a refrigerator. Both of these properties of the vaccine would undoubtedly solve many of the logistical issues healthcare facilities are facing as they try to speed up vaccine distribution.

Click here to read more on this story.